Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 358,685
  • Shares Outstanding, K 167,610
  • Annual Sales, $ 44,510 K
  • Annual Income, $ -70,480 K
  • 60-Month Beta 1.37
  • Price/Sales 8.36
  • Price/Cash Flow N/A
  • Price/Book 5.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.11
  • Number of Estimates 4
  • High Estimate -0.09
  • Low Estimate -0.13
  • Prior Year 0.02
  • Growth Rate Est. (year over year) -650.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.04 +4.90%
on 11/06/19
2.45 -12.65%
on 11/26/19
-0.03 (-1.38%)
since 11/05/19
3-Month
1.56 +37.18%
on 10/18/19
2.45 -12.65%
on 11/26/19
+0.37 (+20.90%)
since 09/05/19
52-Week
1.56 +37.18%
on 10/18/19
2.91 -26.46%
on 12/12/18
-0.73 (-25.44%)
since 12/04/18

Most Recent Stories

More News
Rigel Gets Positive CHMP Review for Thrombocytopenia Drug

The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.

RDHL : 6.46 (+2.22%)
ACRS : 1.68 (-1.18%)
JAZZ : 148.52 (+0.24%)
RIGL : 2.09 (-2.34%)
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive...

RIGL : 2.09 (-2.34%)
Rigel to Present at Jefferies 2019 London Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2019 London Healthcare Conference...

RIGL : 2.09 (-2.34%)
Pharma Sector Tops in October: Best ETFs & Stocks

Pharma sector wins in October, making these ETFs and stocks winners.

PPH : 62.37 (-0.14%)
XPH : 41.00 (-0.56%)
PJP : 63.24 (-0.69%)
ALXN : 109.88 (-4.82%)
BIIB : 286.85 (-0.92%)
ACHN : 6.18 (+0.16%)
DERM : 7.91 (-1.37%)
GLYC : 6.05 (-0.49%)
RIGL : 2.09 (-2.34%)
IRWD : 12.37 (+0.57%)
Rigel Announces Upcoming Data Presentations at the 61st ASH Annual Meeting & Exposition

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets has been accepted for two poster presentations at the 61st American...

RIGL : 2.09 (-2.34%)
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of 36.36% and 28.19%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

RIGL : 2.09 (-2.34%)
Rigel: 3Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported a loss of $11.5 million in its third quarter.

RIGL : 2.09 (-2.34%)
Rigel Announces Third Quarter 2019 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2019, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for...

RIGL : 2.09 (-2.34%)
Clinical Trials in Gene Sequencing Reveal Novel Mutations Aiding in New Treatments for Acute Myeloid Leukemia

Palm Beach, FL -October 29, 2019 - Acute myeloid leukemia (AML), is the most common of the four major types of leukemia. Without treatment, AML is often deadly within a few months. Many of the symptoms...

MBRX : 1.04 (-0.95%)
DCPH : 51.69 (-0.31%)
RIGL : 2.09 (-2.34%)
NKTR : 19.99 (-1.53%)
BDSI : 6.51 (-2.84%)
Rigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2019 financial results after market close on Tuesday, November 5, 2019. Rigel senior management will follow...

RIGL : 2.09 (-2.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade RIGL with:

Business Summary

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year....

See More

Key Turning Points

2nd Resistance Point 2.29
1st Resistance Point 2.22
Last Price 2.09
1st Support Level 2.09
2nd Support Level 2.03

See More

52-Week High 2.91
Fibonacci 61.8% 2.39
Fibonacci 50% 2.24
Last Price 2.09
Fibonacci 38.2% 2.08
52-Week Low 1.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar